Literature DB >> 11862584

Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I.

Connie L Davis1, Thomas A Gonwa, Alan H Wilkinson.   

Abstract

Renal and hepatic function are often intertwined through both the existence of associated primary organ diseases and hemodynamic interrelationships. This connection occasionally results in the chronic failure of both organs, necessitating combined liver-kidney transplantation (LKT). Since 1988, more than 850 patients in the United States have received such transplants, with patient survival somewhat less than that for patients receiving either organ alone. Patients with renal failure caused by acute injury or hepatorenal syndrome have classically not been included as candidates for combined transplantation because of the reversibility of renal dysfunction after liver transplantation. However, the rate and duration of renal failure before liver transplantation is increasing in association with prolonged waiting list times. Thus, the issue of acquired permanent renal damage in the setting of hepatic failure continues to confront the transplant community. The following article and its sequel (Part II, to be published in vol 8, no 3 of this journal) attempt to review the problem of primary and secondary renal disease in patients with end-stage liver disease, elements involved in renal disease progression and recovery, the impact of renal disease on liver transplant outcome, and results of combined LKT; outline the steps in the pretransplantation renal evaluation; and provide the beginnings of an algorithm for making the decision for combined LKT.

Entities:  

Mesh:

Year:  2002        PMID: 11862584     DOI: 10.1053/jlts.2002.31516

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  29 in total

Review 1.  GFR Estimating Equations and Liver Disease.

Authors:  Tomasz Beben; Dena E Rifkin
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

Review 2.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

3.  The impact of MELD allocation on simultaneous liver-kidney transplantation.

Authors:  Julie A Thompson; John R Lake
Journal:  Curr Gastroenterol Rep       Date:  2009-02

4.  Naloxone pretreatment prevents kidney injury after liver ischemia reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Mehran Shahzamani; Ahmad Asghari; Aris Fakouri
Journal:  Int Urol Nephrol       Date:  2016-04-07       Impact factor: 2.370

5.  Updates on Hepato-Renal Syndrome.

Authors:  Kyota Fukazawa; H Thomas Lee
Journal:  J Anesth Clin Res       Date:  2013-09-27

6.  Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review.

Authors:  William R Hand; Joseph R Whiteley; Tom I Epperson; Lauren Tam; Heather Crego; Bethany Wolf; Kenneth D Chavin; David J Taber
Journal:  Anesth Analg       Date:  2015-03       Impact factor: 5.108

7.  Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury.

Authors:  Sang Won Park; Mihwa Kim; Kevin M Brown; Vivette D D'Agati; H Thomas Lee
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 8.  Outcomes of liver transplantation in patients with hepatorenal syndrome.

Authors:  Rohan M Modi; Nishi Patel; Sherif N Metwally; Khalid Mumtaz
Journal:  World J Hepatol       Date:  2016-08-28

9.  Serum sodium, renal function, and survival of patients with end-stage liver disease.

Authors:  Young-Suk Lim; Timothy S Larson; Joanne T Benson; Patrick S Kamath; Walter K Kremers; Terry M Therneau; W Ray Kim
Journal:  J Hepatol       Date:  2010-02-04       Impact factor: 25.083

10.  Sphinganine-1-phosphate attenuates both hepatic and renal injury induced by hepatic ischemia and reperfusion in mice.

Authors:  Sang Won Park; Mihwa Kim; Sean W C Chen; Vivette D D'Agati; H Thomas Lee
Journal:  Shock       Date:  2010-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.